-
BioMarin bought Zacharon to expand its lysosomal storage disease business into brain-specific disorders that can't be treated with enzyme replacement therapy.
Published on 1/28/2013
-
Metabolomx is developing a tool that mimics the olfactory system to detect cancer based on the metabolomic profile of a patient's tumor. The company is initially targeting lung and colon cancer.
Published on 10/22/2012
-
Pfizer thinks partner Visterra's atomic interaction network analysis platform could transform the way in which immunogenic epitopes are identified and developed into antibody candidates.
Published on 10/8/2012
-
GNS Healthcare's deal with Covance to develop predictive clinical trial models for diabetes is one example of how big data tools are being applied to drug development.
Published on 9/24/2012
-
Bristol-Myers is spending pocket change with the hope Summit's Seglin technology can generate stable and target-specific carbohydrate therapeutics. For Summit, the deal is pure upside.
Published on 9/17/2012
-
Pfizer believes Nodality's SCNP technology, which analyzes functional activity within individual cells, could provide early insight into a compound's clinical profile, starting with candidates for lupus.
Published on 8/27/2012
-
e-Therapeutics is branching out into drug discovery, using the same systems biology platform that identified compounds that the company has repurposed and advanced into the clinic.
Published on 7/30/2012
-
Evotec's discovery collaboration with Harvard using the biotech's porcine beta cell screening technology now has led to a development and commercialization deal with J&J.
Published on 7/30/2012
-
Screening beta Growing beta At least five collaborations seeking to discover diabetes candidates that promote beta cell regeneration have been announced since 2009. Drug candidates discovered in the 2011 …
Published on 7/30/2012
-
Boehringer is Polyphor's first partner for the MacroFinder platform, which the biotech says can identify smaller compounds than companies with competing discovery technologies.
Published on 7/16/2012
-
Ra Pharma is emerging from stealth mode two years after securing a $27M A round to build its cyclic peptide platform, which generates molecules containing both natural and modified, unnatural amino acids.
Published on 7/16/2012
-
Merck partnered with Ambrx because the pharma hopes to build upon the biotech's experience in site-specific peptide modification to move antibody-drug conjugates beyond oncology.
Published on 7/9/2012
-
Ensemble now has a third major partnership for its DNA-Programmed Chemistry macrocycle platform, a deal with Genentech to raise drugs against challenging targets.
Published on 6/11/2012
-
Takeda's Millennium subsidiary is using an in vivo screening platform from Presage to speed up preclinical characterization of cancer combination therapies.
Published on 5/7/2012
-
AstraZeneca has concluded that Conformetrix has perfected an NMR-based technology to quickly and accurately determine bioactive conformations of compounds in solution.
Published on 4/30/2012
-
Through early access programs with pharma customers, Cellular Dynamics is gathering data that show its iPS cells predict hepatic and cardiac toxicity better than conventional assays.
Published on 3/26/2012
-
With a new CSO and an injection of venture money, Sutro is ready to pick lead indications where it can use its cell-free biochemical protein synthesis technology to quickly enter the clinic with biosuperiors.
Published on 1/10/2011
-
LineaGen hopes to parlay its efforts to identify rare autism-linked genetic variants into a testing business built around a microarray-based diagnostic platform.
Published on 11/1/2010
-
Advanced Cell Diagnostics has launched a single molecule RNA detection technology it believes will provide a more sensitive level of detection than protein-based assays.
Published on 8/23/2010
-
Cellular Dynamics International Inc. has overcome a technical hurdle that has until now prevented the use of stem cell technologies to …
Published on 1/4/2010
-
Replidyne Inc. last week unveiled REP3123, a MetRS inhibitor in preclinical development that the company thinks will be more effective …
Published on 9/24/2007
-
Technology Small PEGs Over the past decade, Nektar Therapeutics' pegylation capabilities have provided a growing royalty stream via third party sales of biologics that use the technology. Now, internal products that…
Published on 9/24/2007
-
Technology Targeting mucosal inflammation Biogen Idec Inc. has long been interested in the late stages of inflammation where tissue remodeling and fibrosis occur. Last week's deal with LigoCyte Pharmaceuticals Inc. …
Published on 9/24/2007
-
Technology Complementing MAbs Biothera thinks its Imprime PGG beta-glucan, a soluble carbohydrate, could be combined with complement-fixing MAbs to improve their efficacy compared to the MAbs alone in some cancers.…
Published on 9/17/2007
-
Technology Ready, steady, glow Researchers at Stanford University School of Medicine have developed an advanced activity-based probe they say will allow drug companies to make faster, earlier and perhaps even …
Published on 9/17/2007